
China’s top mRNA contender is ready to go. And SoftBank just led a cash infusion pushing it over the $1B line
With Moderna and BioNTech offering a model — in the US and Europe, respectively — for how mRNA biotechs can enjoy a meteoric rise to profit and fame with just one successful Covid-19 vaccine, a Chinese player is ready to put itself on the map.
Abogen, which set a record just three months ago with a $720 million Series C, has now raised another $300 million as it prepares to file its vaccine candidate for authorization. Partnered with Walvax and China’s military, ABO-028M first entered clinical testing in the summer of 2020 and is now in Phase III trials in Mexico, Indonesia and Nepal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.